Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal.

Slides:

Advertisements

Similar presentations

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Tuomo Puhakka, MDa, Mika J

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome Paul Steinberg, MDa, Bruce E.

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction Robert A. Nathan, MDa, Jonathan A.

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis William R. Lumry, MD Journal of.

Quantitative IgE antibody assays in allergic diseases

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Richard L. ZuWallack, MD a,b, James P

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Badrul A. Chowdhury, MD, PhD

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Edwin A. Bronsky, MD, Howard Druce, MD, Steven R. Findlay, MD, Frank C

Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis.

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Conjunctivitis medicamentosa

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic.

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

A review of the current guidelines for allergic rhinitis and asthma

Physician-targeted program on inhaled therapy for childhood asthma

News & Notes Journal of Allergy and Clinical Immunology

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis Sakari Reitamo, MDa,

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with.

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients.

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

News & Notes Journal of Allergy and Clinical Immunology

The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis Anjuli S. Nayak, MDa, Mark H.

Fluticasone propionate powder: Oral corticosteroid–sparing effect and improved lung function and quality of life in patients with severe chronic asthma

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

The 30th anniversary of the American Board of Allergy and Immunology: Then and now Lynn Des Prez a, Charles E. Reed, MD, Lawrence B. Schwartz, MDb, John.

A prospective, controlled study showing that rubber gloves are the major contributor to latex aeroallergen levels in the operating room Dann K. Heilman,

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis Matthias Volkmar Kopp, MDa, Jens Brauburger,

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing.

Anaphylaxis after initial ingestion of rambutan, a tropical fruit

Tuomo Puhakka, MDa, Mika J

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Larry C. Borish, MDa, Harold S

Quantification of conjunctival vascular reaction by digital imaging

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

News & Notes Journal of Allergy and Clinical Immunology

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Desloratadine: A new, nonsedating, oral antihistamine

Presentation transcript:

Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis Edwin Bronsky, MDa, Peter Boggs, MDb, Steven Findlay, MDc, Sandra Gawchik, DOd, John Georgitis, MDe, Herbert Mansmann, MDf, Lawrence Sholler, MDg, James Wolfe, MDh, Eli Meltzer, MDi, Richard Morris, MDj, Zev Munk, MDk, Barry Paull, MDl, Warren Pleskow, MDm, Paul Ratner, MDn, Melvyn Danzig, PhDo, Judy Harrison, MDo, Richard Lorber, MDo Journal of Allergy and Clinical Immunology Volume 96, Issue 2, Pages 139-147 (August 1995) DOI: 10.1016/S0091-6749(95)70001-3 Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 1 Mean reduction from baseline in mean total symptoms. Sum of rhinorrhea, stuffiness, itching, sneezing, itching or burning eyes, tearing, redness, itching of ears or palate. On day 4: SCH 434 QD and loratadine versus pseudoephedrine and placebo, p ≤ 0.01. At end point: SCH 434 QD versus loratadine, pseudoephedrine, and placebo, p ≤ 0.05. Overall: SCH 434 QD and loratadine versus placebo, p ≤ 0.01; SCH 434 QD versus pseudoephedrine, p < 0.01. Journal of Allergy and Clinical Immunology 1995 96, 139-147DOI: (10.1016/S0091-6749(95)70001-3) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 2 Mean reduction from baseline in mean total nasal symptoms. Sum of rhinorrhea, stuffiness, itching, and sneezing. On day 4: all active treatments versus placebo, p < 0.01; SCH 434 QD versus pseudoephedrine, p = 0.05. At end point: SCH 434 QD versus placebo, p < 0.01; SCH 434 QD versus loratadine, p < 0.01; pseudoephedrine versus placebo, p < 0.01. Overall: all active treatments versus placebo, p < 0.01. Journal of Allergy and Clinical Immunology 1995 96, 139-147DOI: (10.1016/S0091-6749(95)70001-3) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 3 Mean reduction from baseline in mean total nonnasal symptoms. Sum of burning or itching eyes, tearing eyes, red eyes, and itching of ears or palate. On day 4: SCH 434 QD versus placebo and pseudoephedrine, p < 0.01; loratadine versus pseudoephedrine and placebo, p < 0.01. At end point: SCH 434 QD versus placebo and pseudoephedrine, p < 0.01; loratadine versus pseudoephedrine and placebo, p ≤ 0.03. Overall: SCH 434 QD and loratadine versus pseudoephedrine and placebo, p < 0.01. Journal of Allergy and Clinical Immunology 1995 96, 139-147DOI: (10.1016/S0091-6749(95)70001-3) Copyright © 1995 Mosby, Inc. Terms and Conditions

FIG. 4 Mean reduction from baseline in mean nasal stuffiness. On day 4 and at end point: SCH 434 QD versus placebo, p ≤ 0.03; pseudoephedrine versus placebo, p ≤ 0.05. At end point: SCH 434 QD and pseudoephedrine versus loratadine, p < 0.01. Overall: SCH 434 QD versus loratadine and placebo, p ≤ 0.02; pseudoephedrine versus placebo, p = 0.04. Journal of Allergy and Clinical Immunology 1995 96, 139-147DOI: (10.1016/S0091-6749(95)70001-3) Copyright © 1995 Mosby, Inc. Terms and Conditions